Welcome to our dedicated page for Evolus news (Ticker: EOLS), a resource for investors and traders seeking the latest updates and insights on Evolus stock.
Evolus, Inc. commercializes cash-pay medical aesthetic products for the global performance beauty market. Its portfolio centers on Jeuveau® (prabotulinumtoxinA-xvfs), known as Nuceiva® outside the United States, and injectable hyaluronic acid gel collections marketed under the Evolysse® and Estyme® brands.
Recurring Evolus news includes quarterly financial results, revenue outlooks, product and market expansion for injectable aesthetics, CE Mark certification for HA gel collections, national-account and customer engagement updates, healthcare conference participation, and equity compensation grants under Nasdaq inducement rules. Company updates also discuss operations across the United States, Canada, Europe, and Australia.
Evolus (NASDAQ: EOLS) reported second quarter 2026 net revenue of $84.1 million, up 21% year over year, including $75.2 million from global toxin products and $8.9 million from injectable hyaluronic acid (HA) gels. GAAP loss from operations was $4.5 million, while Adjusted EBITDA was positive $4.7 million, marking a third consecutive quarter of positive Adjusted EBITDA and a $12.6 million improvement over the prior-year period.
Gross margin was 68.0% and adjusted gross margin 69.0%, aided by ~120 basis points from a tariff refund. As of June 30, 2026, cash and cash equivalents were $45.2 million. Evolus raised 2026 net revenue guidance to $330–$337 million, increased adjusted gross margin guidance to 67.0%–67.5%, and narrowed non-GAAP operating expenses to $212–$216 million, while reaffirming a low- to mid-single digit Adjusted EBITDA margin outlook and its 2028 targets of $450–$500 million revenue and 13%–15% Adjusted EBITDA margin.
Strategically, Evolus launched its Estyme HA gel line in Europe, expanded its Symatese licensing deal to Canada, Australia and New Zealand, secured exclusive U.S. rights to develop and commercialize Profhilo, and continued advancing Evolysse Sculpt through FDA review.
Evolus (NASDAQ:EOLS) expanded its strategic partnership with Symatese via an amendment to their licensing and distribution agreement, granting Evolus exclusive rights to commercialize the Estyme injectable hyaluronic acid (HA) gel collection in Canada, Australia, and New Zealand.
Commercialization is expected in 2028, subject to regulatory approvals. With this deal, Evolus will hold exclusive rights to its injectable HA gel portfolio in every market where it currently sells Jeuveau and Nuceiva, creating a consistent multi-product platform. Symatese retains responsibility for development, manufacturing, clinical support, and regulatory activities. Evolus will pay an upfront fee, regulatory milestone payments, product transfer price, and a mid-single digit royalty on net sales. According to Evolus, the agreement should be accretive to international gross margins and leverages existing commercial and digital infrastructure across these markets, which together represent an estimated $500 million annual neurotoxin and dermal filler market.
Evolus (NASDAQ:EOLS) will release its second quarter 2026 financial results on Wednesday, August 5, 2026, after the U.S. markets close. Management will host a conference call and live webcast at 4:30 p.m. ET, followed by a Q&A session and providing replay and archived webcast access.
Evolus (NASDAQ: EOLS) reported that from April 2026 through July 2026 it granted an aggregate of 115,000 restricted stock units (RSUs) to 38 newly hired non-executive employees. The RSUs, issued under the 2023 Inducement Incentive Plan, vest 25% annually starting on grant-specific vesting commencement dates, contingent on continuous employment and made in accordance with Nasdaq Listing Rule 5635(c)(4).
Evolus (NASDAQ:EOLS) entered an exclusive licensing and distribution agreement with Swiss pharma company IBSA to develop and commercialize Profhilo in the United States. Profhilo is a market-leading injectable for skin quality in Europe, sold in 70+ countries with over 4.8 million treatments.
Evolus will handle U.S. regulatory development and commercialization. The deal has no upfront payments, uses a transfer-price model to support gross margins, and is not expected to change 2026 revenue or 2028 profitability targets.
Evolus (NASDAQ:EOLS) announced that its management team will participate in a fireside chat and investor meetings at the Jefferies Global Healthcare Conference in New York City.
The fireside chat is scheduled for Thursday, June 4, 2026, at 12:50 PM ET and will be webcast with a 90-day replay.
Evolus (NASDAQ:EOLS) will commercially launch its Estyme injectable hyaluronic acid gel collection in Europe on May 16, marking entry into the international dermal filler market. The CE‑marked portfolio includes Estyme Smooth, Form, Lips and flagship Sculpt, supported by pivotal studies and Cold-X technology for natural-looking, long-lasting results.
Evolus (NASDAQ: EOLS) reported Q1 2026 net revenue $73.1M, up 7% year-over-year, with GAAP operating loss $6.8M and Adjusted EBITDA $0.6M (second consecutive quarter positive). The company reaffirmed 2026 guidance of $327M–$337M revenue and $210M–$216M non-GAAP operating expenses, and noted cash of $49.8M. Key commercial milestones include an Estyme Europe launch in mid-May and anticipated U.S. approval of Evolysse Sculpt in Q4 2026.
Evolus (NASDAQ: EOLS) will report its first quarter 2026 financial results on Monday, May 4, 2026, after U.S. markets close. Management will host a conference call and live webcast the same day at 4:30 p.m. ET, followed by a Q&A session.
Dial-in numbers, a telephonic replay and an archived webcast will be available via the company's Investor Relations page.
Evolus (NASDAQ: EOLS) said members of its management team will join a fireside chat and investor meetings at the Needham 25th Annual Virtual Healthcare Conference on April 14, 2026 at 3:45 PM ET.
According to Evolus, the live webcast is accessible on the company Investor Relations page and a replay will be available for 90 days after the presentation.